Yes very strange what DSMC did in CD12 during interim at 50% ..
“ Continue what you doing , don’t change anything , do another interim at 75% , and mortality endpoint not at 28 days but 42 “
This look like another sabotage of the study , continue 2 treatment but primary endpoint , mortality in 42 days ???
Why ???
Picture here show very specifically that more doses are needed . And Dr Lalezari asked this question ..
When injection done only at 0 and 7 days , and at 7 days mortality benefit above SOC drugs is 78% , at 14 days is 82% , but at 21 days is 50 and at 28 , is 31% .,
It is a very clear picture , 2 doses are not enough ..
Market Data 
Markets 
AI
